Which has better earnings and valuation, ARGX or ROIV?

argenex has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.25B 12.92 $1.29B $22.46 39.29 Roivant Sciences $8.26M 2,480.87 -$299.77M -$0.60 N/A

Is ARGX or ROIV more profitable?

argenex has a net margin of 31.31% compared to Roivant Sciences' net margin of -3,629.19%. argenex's return on equity of 44.37% beat Roivant Sciences' return on equity. Company Net Margins Return on Equity Return on Assets argenex 31.31% 44.37% 37.55% Roivant Sciences -3,629.19% -20.54% -19.43%

Does the media favor ARGX or ROIV?

In the previous week, Roivant Sciences had 5 more articles in the media than argenex. MarketBeat recorded 12 mentions for Roivant Sciences and 7 mentions for argenex. Roivant Sciences' average media sentiment score of 1.27 beat argenex's score of 0.52 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 9 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate TAK or ROIV?

Roivant Sciences has a consensus target price of $33.59, indicating a potential upside of 17.90%. Given Roivant Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Roivant Sciences is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Roivant Sciences 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.75

Does the media prefer TAK or ROIV?

In the previous week, Roivant Sciences had 10 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 12 mentions for Roivant Sciences and 2 mentions for Takeda Pharmaceutical. Roivant Sciences' average media sentiment score of 1.27 beat Takeda Pharmaceutical's score of 0.80 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 9 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ROIV or TEVA?

In the previous week, Teva Pharmaceutical Industries had 22 more articles in the media than Roivant Sciences. MarketBeat recorded 34 mentions for Teva Pharmaceutical Industries and 12 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.27 beat Teva Pharmaceutical Industries' score of 1.18 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 9 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Teva Pharmaceutical Industries 27 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ROIV or RVMD?

In the previous week, Revolution Medicines had 2 more articles in the media than Roivant Sciences. MarketBeat recorded 14 mentions for Revolution Medicines and 12 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.27 beat Revolution Medicines' score of 0.44 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 9 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ONC or ROIV?

In the previous week, Roivant Sciences had 3 more articles in the media than BeOne Medicines. MarketBeat recorded 12 mentions for Roivant Sciences and 9 mentions for BeOne Medicines. Roivant Sciences' average media sentiment score of 1.27 beat BeOne Medicines' score of 0.92 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 9 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Roivant Sciences (ROIV) Competitors

$28.49 -0.09 (-0.31%)

Closing price 04:00 PM Eastern

Extended Trading

$28.25 -0.24 (-0.84%)

As of 07:42 PM Eastern

Compare

ROIV vs. ARGX, TAK, TEVA, RVMD, and ONC

Should you buy Roivant Sciences stock or one of its competitors? MarketBeat compares Roivant Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Roivant Sciences include argenex (ARGX), Takeda Pharmaceutical (TAK), Teva Pharmaceutical Industries (TEVA), Revolution Medicines (RVMD), and BeOne Medicines (ONC). These companies are all part of the "pharmaceutical products" industry.

How does Roivant Sciences compare to argenex?

argenex (NASDAQ:ARGX) and Roivant Sciences (NASDAQ:ROIV) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

argenex has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market.

argenex has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	12.92	$1.29B	$22.46	39.29
Roivant Sciences	$8.26M	2,480.87	-$299.77M	-$0.60	N/A

In the previous week, Roivant Sciences had 5 more articles in the media than argenex. MarketBeat recorded 12 mentions for Roivant Sciences and 7 mentions for argenex. Roivant Sciences' average media sentiment score of 1.27 beat argenex's score of 0.52 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	9 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

argenex presently has a consensus price target of $1,019.50, suggesting a potential upside of 15.54%. Roivant Sciences has a consensus price target of $33.59, suggesting a potential upside of 17.90%. Given Roivant Sciences' higher probable upside, analysts plainly believe Roivant Sciences is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

60.3% of argenex shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 2.4% of argenex shares are owned by company insiders. Comparatively, 10.8% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

argenex has a net margin of 31.31% compared to Roivant Sciences' net margin of -3,629.19%. argenex's return on equity of 44.37% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	31.31%	44.37%	37.55%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

Summary

argenex beats Roivant Sciences on 10 of the 17 factors compared between the two stocks.

How does Roivant Sciences compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and Roivant Sciences (NASDAQ:ROIV) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

Roivant Sciences has a consensus target price of $33.59, indicating a potential upside of 17.90%. Given Roivant Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Roivant Sciences is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Takeda Pharmaceutical has a beta of -0.07, meaning that its share price is 107% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market.

Takeda Pharmaceutical has a net margin of 4.31% compared to Roivant Sciences' net margin of -3,629.19%. Takeda Pharmaceutical's return on equity of 11.07% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	4.31%	11.07%	5.49%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

Takeda Pharmaceutical has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	1.77	$1.27B	$0.39	40.45
Roivant Sciences	$8.26M	2,480.87	-$299.77M	-$0.60	N/A

In the previous week, Roivant Sciences had 10 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 12 mentions for Roivant Sciences and 2 mentions for Takeda Pharmaceutical. Roivant Sciences' average media sentiment score of 1.27 beat Takeda Pharmaceutical's score of 0.80 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	9 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Comparatively, 10.8% of Roivant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Roivant Sciences beats Takeda Pharmaceutical on 9 of the 16 factors compared between the two stocks.

How does Roivant Sciences compare to Teva Pharmaceutical Industries?

Roivant Sciences (NASDAQ:ROIV) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

Teva Pharmaceutical Industries has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	2,480.87	-$299.77M	-$0.60	N/A
Teva Pharmaceutical Industries	$17.26B	2.21	$1.41B	$1.33	24.99

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Roivant Sciences' net margin of -3,629.19%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

In the previous week, Teva Pharmaceutical Industries had 22 more articles in the media than Roivant Sciences. MarketBeat recorded 34 mentions for Teva Pharmaceutical Industries and 12 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.27 beat Teva Pharmaceutical Industries' score of 1.18 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	9 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	27 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Roivant Sciences currently has a consensus price target of $33.59, suggesting a potential upside of 17.90%. Teva Pharmaceutical Industries has a consensus price target of $41.78, suggesting a potential upside of 25.70%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Roivant Sciences has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market.

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 10.8% of Roivant Sciences shares are owned by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Teva Pharmaceutical Industries beats Roivant Sciences on 10 of the 16 factors compared between the two stocks.

How does Roivant Sciences compare to Revolution Medicines?

Roivant Sciences (NASDAQ:ROIV) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

Revolution Medicines has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Revolution Medicines	N/A	-83.22%	-59.06%

In the previous week, Revolution Medicines had 2 more articles in the media than Roivant Sciences. MarketBeat recorded 14 mentions for Revolution Medicines and 12 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.27 beat Revolution Medicines' score of 0.44 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	9 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Roivant Sciences has higher earnings, but lower revenue than Revolution Medicines. Roivant Sciences is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	2,480.87	-$299.77M	-$0.60	N/A
Revolution Medicines	$11.58M	2,726.16	-$1.13B	-$7.07	N/A

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by company insiders. Comparatively, 7.6% of Revolution Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Roivant Sciences has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

Roivant Sciences presently has a consensus target price of $33.59, indicating a potential upside of 17.90%. Revolution Medicines has a consensus target price of $123.72, indicating a potential downside of 16.68%. Given Roivant Sciences' higher possible upside, analysts clearly believe Roivant Sciences is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00

Summary

Revolution Medicines beats Roivant Sciences on 10 of the 17 factors compared between the two stocks.

How does Roivant Sciences compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Roivant Sciences (NASDAQ:ROIV) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

BeOne Medicines currently has a consensus price target of $390.00, indicating a potential upside of 44.02%. Roivant Sciences has a consensus price target of $33.59, indicating a potential upside of 17.90%. Given BeOne Medicines' stronger consensus rating and higher possible upside, equities research analysts plainly believe BeOne Medicines is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

BeOne Medicines has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	5.56	$286.93M	$4.47	60.58
Roivant Sciences	$8.26M	2,480.87	-$299.77M	-$0.60	N/A

BeOne Medicines has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market.

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by company insiders. Comparatively, 10.8% of Roivant Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

BeOne Medicines has a net margin of 8.94% compared to Roivant Sciences' net margin of -3,629.19%. BeOne Medicines' return on equity of 12.06% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

In the previous week, Roivant Sciences had 3 more articles in the media than BeOne Medicines. MarketBeat recorded 12 mentions for Roivant Sciences and 9 mentions for BeOne Medicines. Roivant Sciences' average media sentiment score of 1.27 beat BeOne Medicines' score of 0.92 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	9 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BeOne Medicines beats Roivant Sciences on 11 of the 17 factors compared between the two stocks.

Get Roivant Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ROIV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ROIV vs. The Competition

Export

Metric	Roivant Sciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$20.56B	$3.34B	$6.49B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.57%
P/E Ratio	-47.48	18.61	23.92	23.74
Price / Sales	2,480.87	298.43	507.57	108.00
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	3.88	8.04	10.28	6.78
Net Income	-$299.77M	$23.89M	$3.57B	$337.51M
7 Day Performance	-2.06%	-5.97%	-1.43%	-2.72%
1 Month Performance	-0.25%	2.78%	3.27%	1.87%
1 Year Performance	153.70%	36.26%	23.37%	26.60%

Roivant Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ROIV Roivant Sciences	3.1963 of 5 stars	$28.49 -0.3%	$33.59 +17.9%	+154.5%	$20.56B	$8.26M	N/A	860	Positive News Gap Down
ARGX argenex	3.5518 of 5 stars	$836.09 +0.0%	$1,019.50 +21.9%	+52.1%	$51.99B	$4.66B	37.23	1,863	News Coverage
TAK Takeda Pharmaceutical	3.578 of 5 stars	$15.20 -4.8%	N/A	+4.3%	$50.79B	$28.32B	38.96	47,455
TEVA Teva Pharmaceutical Industries	4.8927 of 5 stars	$34.51 -2.3%	$41.78 +21.1%	+92.6%	$40.61B	$17.35B	25.95	33,950	Positive News Analyst Upgrade
RVMD Revolution Medicines	2.1238 of 5 stars	$163.68 +3.9%	$122.78 -25.0%	+263.2%	$33.48B	$11.58M	N/A	250	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ROIV) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Roivant Sciences (ROIV) Competitors

ROIV vs. ARGX, TAK, TEVA, RVMD, and ONC

How does Roivant Sciences compare to argenex?

Summary

How does Roivant Sciences compare to Takeda Pharmaceutical?

Summary

How does Roivant Sciences compare to Teva Pharmaceutical Industries?

Summary

How does Roivant Sciences compare to Revolution Medicines?

Summary

How does Roivant Sciences compare to BeOne Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ROIV vs. The Competition

Roivant Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Roivant Sciences (ROIV) Competitors

ROIV vs. ARGX, TAK, TEVA, RVMD, and ONC

How does Roivant Sciences compare to argenex?

Which has more risk and volatility, ARGX or ROIV?

Which has better earnings and valuation, ARGX or ROIV?

Does the media favor ARGX or ROIV?

Do analysts rate ARGX or ROIV?

Do institutionals & insiders hold more shares of ARGX or ROIV?

Is ARGX or ROIV more profitable?

Summary

How does Roivant Sciences compare to Takeda Pharmaceutical?

Do analysts rate TAK or ROIV?

Which has more volatility and risk, TAK or ROIV?

Is TAK or ROIV more profitable?

Which has preferable valuation & earnings, TAK or ROIV?

Does the media prefer TAK or ROIV?

Do insiders & institutionals believe in TAK or ROIV?

Summary

How does Roivant Sciences compare to Teva Pharmaceutical Industries?

Which has preferable earnings & valuation, ROIV or TEVA?

Is ROIV or TEVA more profitable?

Does the media favor ROIV or TEVA?

Do analysts rate ROIV or TEVA?

Which has more volatility and risk, ROIV or TEVA?

Do insiders and institutionals hold more shares of ROIV or TEVA?

Summary

How does Roivant Sciences compare to Revolution Medicines?

Is ROIV or RVMD more profitable?

Does the media favor ROIV or RVMD?

Which has preferable valuation & earnings, ROIV or RVMD?

Do insiders and institutionals believe in ROIV or RVMD?

Which has more volatility and risk, ROIV or RVMD?

Do analysts prefer ROIV or RVMD?

Summary

How does Roivant Sciences compare to BeOne Medicines?

Do analysts prefer ONC or ROIV?

Which has preferable earnings & valuation, ONC or ROIV?

Which has more volatility and risk, ONC or ROIV?

Do insiders and institutionals have more ownership in ONC or ROIV?

Is ONC or ROIV more profitable?

Does the media refer more to ONC or ROIV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ROIV vs. The Competition

Roivant Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools